RBC Capital Affirms Amgen (AMGN) at 'Outperform'; Repatha Approval Similar to Praluent (REGN) (SNY)
Tweet Send to a Friend
RBC Capital is out with commentary on Amgen (Nasdaq: MGN) following news that the U.S. FDA apprvoed the company's new ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
